134 filings
Page 3 of 7
6-K
xdl9kstk4kqbz
13 Nov 23
NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter 2023 Financial Highlights
12:00am
6-K
emc0a0ryw5smixo2lar
23 Oct 23
NewAmsterdam Pharma Announces Appointment of Ian Somaiya as Chief Financial Officer
8:12am
6-K
lthw2rihs217bx
25 Sep 23
Current report (foreign)
8:10am
424B3
uahyyg0z
21 Sep 23
Prospectus supplement
7:18am
6-K
5pl947viea
21 Sep 23
NewAmsterdam Pharma Announces Initial Data from Phase 2a Clinical Trial Evaluating Obicetrapib in Patients
7:14am
6-K
2jpe5jq6
28 Aug 23
Current report (foreign)
4:16pm
424B3
yfqj h0uie78klzb
15 Aug 23
Prospectus supplement
4:52pm
6-K
n4zjgyu495o1h7tc 0a
14 Aug 23
NewAmsterdam Pharma Announces Appointment of William “BJ” Jones, formerly of Biohaven Pharmaceuticals, as Chief Commercial Officer
4:52pm
EFFECT
c6ts hblnpa8ts5g
14 Aug 23
Notice of effectiveness
12:15am
POS AM
qcrg jcsk956
7 Aug 23
Prospectus update (post-effective amendment)
7:56am
6-K
5a3 jx4on
7 Aug 23
NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter 2023 Financial Highlights
7:38am
6-K
4bm9lkm4q1bw
7 Aug 23
Research and development expenses
7:24am
6-K
3b0ng2zi6 zy8vi
26 Jul 23
NewAmsterdam Pharma Completes Enrollment in Pivotal Phase 3 BROADWAY Clinical Trial Evaluating
8:00am
424B3
o331h66rx83e0 8kc9d
21 Jun 23
Prospectus supplement
4:04pm
6-K
1abs5
21 Jun 23
Current report (foreign)
4:01pm
424B3
y6ii6m6kvl 0iw
9 Jun 23
Prospectus supplement
9:43pm
6-K
f0ln1nqsl8xnjw66j4z
9 Jun 23
Current report (foreign)
9:39pm
424B3
5py29njfyana1l
8 Jun 23
Prospectus supplement
5:01pm
424B3
x3qqtiqnr6zpsrns1g66
6 Jun 23
Prospectus supplement
4:20pm
6-K
qx7qvnw0q3m0ex
5 Jun 23
Current report (foreign)
8:50am